[68Ga]Ga-PSMA-11 PET/CT(MRI)在前列腺癌根治术后挽救性淋巴结清扫中淋巴结分期的前瞻性评估
该前瞻性研究纳入65例根治性前列腺切除术后生化复发患者,在行超扩大挽救性淋巴结清扫前接受[68Ga]Ga-PSMA-11 PET/CT(MRI)检查。区域分析显示灵敏度72%–100%、特异度96%–100%,阳性预测值95%–100%、阴性预测值93%–100%。PET阳性淋巴结中位直径7.2 mm,PET阴性区域转移淋巴结中位直径3.4 mm。
要点
- PSMA-11 PET/CT(MRI)对生化复发患者淋巴结转移识别性能很好。
- 区域分析灵敏度72%–100%、特异度96%–100%。
- 诊断性能依赖于PSA水平和转移灶大小。
核心结论
- PSMA-11 PET/CT(MRI)在根治性前列腺切除术后生化复发患者中识别淋巴结转移具有很好的性能。
- 区域和亚区域分析的高诊断准确性提示该手段有潜力实现按区域定向而非完全双侧的治疗干预。
- PSMA-11 PET/CT(MRI)的性能取决于PSA水平和转移灶大小。
研究设计与样本
- 前瞻性研究纳入65例根治性前列腺切除术后出现生化复发的连续患者,2014至2018年间在PSMA-11 PET/CT(MRI)后接受挽救性淋巴结清扫。
- 所有患者均行至肠系膜下动脉水平的扩大挽救性淋巴结清扫。
- 评估组织病理学淋巴结转移与全身PSMA-11 PET/CT(MRI)结果在区域和模板基础上的相关性。
- 根据挽救性淋巴结清扫时的PSA水平评估PSMA-11 PET/CT(MRI)的诊断准确性。
主要发现
- 挽救性淋巴结清扫时患者中位年龄65岁(IQR 63–69岁),中位PSA水平1.4 ng/ml(IQR 0.8–2.9 ng/ml)。
- 挽救性淋巴结清扫前,50例(77%)患者在根治性前列腺切除术后接受过额外治疗(26.2%雄激素剥夺治疗,50.8%放疗)。
- 挽救性淋巴结清扫切除淋巴结中位数40枚(IQR 33–48),阳性淋巴结中位数4枚(IQR 2–6)。
- 切除淋巴结中13.8%(317/2292)见淋巴结转移。
- PSMA-11 PET/CT(MRI)阳性淋巴结中位直径7.2 mm(IQR 5.3–9 mm),PET阴性区域转移淋巴结中位直径3.4 mm(IQR 2.1–5.4 mm)。
关键数值与推荐
- 区域分析中PSMA-11 PET/CT(MRI)灵敏度范围为72%至100%,特异度范围为96%至100%。
- 区域特异性阳性预测值和阴性预测值范围分别为95%至100%和93%至100%。
临床怎么用
- PSMA-11 PET/CT(MRI)可用于根治性前列腺切除术后生化复发患者的淋巴结分期评估。
- 区域和亚区域分析的高诊断准确性支持基于PET结果进行区域定向治疗干预的潜力。
- 判读时应考虑PSA水平和转移灶大小对诊断性能的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the accuracy of [68Ga]-PSMA-11 PET/CT or [68Ga]-PSMA-11 PET/MRI (PSMA-11 PET/CT(MRI)) for lymph node (LN) staging using salvage LN dissection (SLND) in patients with biochemical recurrence (BCR) after radical prostatectomy (RP). PATIENTS AND METHODS: In a prospective study, 65 consecutive patients who developed BCR after RP underwent SLND after PSMA-11 PET/CT(MRI) between 2014 and 2018. Extended SLND up to the inferior mesenteric artery was performed in all patients. Regional and template-based correlations between the presence of LN metastases on histopathology and whole-body PSMA-11 PET/CT(MRI) results were evaluated. The diagnostic accuracy of PSMA-11 PET/CT(MRI) was also evaluated in relation to PSA level at the time of SLND. RESULTS: The median age of the patients at the time of SLND was 65 years (IQR 63-69 years) and the median PSA level was 1.4 ng/ml (IQR 0.8-2.9 ng/ml). Before SLND, 50 patients (77%) had additional therapy after RP (26.2% androgen-deprivation therapy and 50.8% radiotherapy). The median number of LNs removed on SLND was 40 (IQR 33-48) and the median number of positive nodes was 4 (IQR 2-6). LN metastases were seen in 13.8% of resected LNs (317 of 2,292). LNs positive on PSMA-11 PET/CT(MRI) had a median diameter of 7.2 mm (IQR 5.3-9 mm). Metastatic LNs in regions negative on PSMA-11 PET had a median diameter of 3.4 mm (IQR 2.1-5.4 mm). In a regional analysis, the sensitivity of PSMA-11 PET/CT(MRI) ranged from 72% to 100%, and the specificity from 96% to 100%. Region-specific positive and negative predictive values ranged from 95% to 100% and 93% to 100%, respectively. CONCLUSION: PSMA-11 PET/CT(MRI) has a very good performance for the identification of LN metastases in patients with BCR after RP. The high diagnostic accuracy in the regional and subregional analyses demonstrates the potential of this approach to enable a region-directed instead of a complete bilateral therapeutic intervention. The performance of PSMA-11 PET/CT(MRI) is dependent on the PSA level and the size of the metastatic deposit.
引用
- Abufaraj M, Grubmüller B, Zeitlinger M, et al. Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2019. PMID: 31254037. doi:10.1007/s00259-019-04361-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。